SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: s Cooperative Group Study. J Clin Oncol. 1997; 15: 25642569.
  • 2
    Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 1994; 12: 22642270.
  • 3
    Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997; 15: 33943398.
  • 4
    McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997; 15: 18531857.
  • 5
    Vaughn DJ, Malkowicz SB. Recent advances in bladder cancer chemotherapy. Cancer Invest. 2001; 19: 7785.
  • 6
    Bhargava P, Marshall JL, Williams FK, et al. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer. Cancer Chemother Pharmacol. 2001; 48: 95103.
  • 7
    Dunsford ML, Mead GM, Bateman AC, Cook T, Tung K. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol. 1999; 10: 943947.
  • 8
    Raghavan D. Advanced bladder and urothelial cancers. Eur J Cancer. 2000; 36 (Suppl 2): 16.
  • 9
    Witte RS, Elson P, Bono B, et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol. 1997; 15: 589593.
  • 10
    McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma. J Clin Oncol. 1997; 15: 24492455.
  • 11
    Krege S, Rembrink V, Borgermann CH, Otto T, Rubben H. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. J Urol. 2001; 165: 6771.
  • 12
    Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000; 18: 35583585.
  • 13
    Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649655.
  • 14
    Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999; 17: 31733181.
  • 15
    Sweeney CJ, Williams SD, Finch DE, et al. A phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer. 1999; 86: 514518.
  • 16
    Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer. 2001; 92: 29932998.
  • 17
    Lorusso V, Pollera CF, Antimi M, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur J Cancer. 1998; 34: 12081212.
  • 18
    Albers P, Siener R, Hartlein M, et al. Gemcitabine monotherapy as second-line treatment in cisplatin refractory transitional cell carcinoma-prognostic factors for response and improvement of quality of life. Onkologie. 2002; 25: 47– 52.